

IN THE CLAIMS:

1-31. (Canceled)

32. (Previously Presented) A pharmaceutical composition for the treatment of female hormonal deficiencies consisting essentially of:

a mixture of estrogenic compounds, wherein said mixture comprises salts of conjugated estrone, conjugated equilin, conjugated $\Delta^{8,9}$ -dehydroestrone, conjugated 17α -estradiol, conjugated 17β -dihydroequilin, conjugated 17α -dihydroequilin, conjugated 17β -estradiol, conjugated equilenin, conjugated 17α -dihydroequilenin, and conjugated 17β -dihydroequilenin;

a therapeutically effective amount of a non-aromatizing androgenic compound, wherein the non-aromatizing androgenic compound is selected from the group consisting of oxandrolone, oxymetholone, stanozolol, danazol, pharmaceutically acceptable esters and salts thereof, and combinations of any of the foregoing; and

a pharmaceutically acceptable carrier.

33. (Canceled)

34. (Previously Presented) A pharmaceutical composition for the treatment of female hormonal deficiencies consisting essentially of:

a mixture of estrogenic compounds, wherein said mixture comprises salts of conjugated estrone, conjugated equilin, conjugated $\Delta^{8,9}$ -dehydroestrone, conjugated 17α -estradiol, conjugated 17β -dihydroequilin, conjugated 17α -dihydroequilin, conjugated 17β -estradiol, conjugated equilenin, conjugated 17α -dihydroequilenin, and conjugated 17β -dihydroequilenin;

a therapeutically effective amount of a non-aromatizing androgenic compound, wherein the non-aromatizing androgenic compound is selected from the group consisting of oxandrolone, oxymetholone, stanozolol, danazol, pharmaceutically acceptable esters and salts thereof, and combinations of any of the foregoing;

a therapeutically effective amount of a progestin compound; and

a pharmaceutically acceptable carrier.

In re: Leonard et al.
Serial No.: 10/029,424
Filed: December 20, 2001
Page 3 of 7

35. (Canceled)